AUG 29, 2020 7:34 AM PDT

MDMA and LSD Combo to Enter Clinical Trials

WRITTEN BY: Annie Lennon

Scientists from the pharmaceutical company, MindMed, have announced the beginning of Phase 1 clinical trials to test Schedule 1 drugs MDMA and LSD. The trial will commence in Basel, Switzerland, later this year, and is the first robust clinical trial to investigate how the two drugs work together. 

For the study, the researchers will recruit 24 healthy subjects to undergo four different experimental sessions. In one session, participants will be dosed with 100 micrograms of LSD mixed alongside an MDMA placebo. In another, they will receive an LSD placebo and 100 milligrams of MDMA. In the last two, they will receive placebos both for LSD and MDMA, and 100 micrograms of LSD accompanied by 100 milligrams of MDMA. 

Alongside each combination's subjective effects, the researchers will also assess measures, including heart rate, blood pressure, and body temperature. Until now, they suspect that the two drugs may work synergistically to deliver better therapeutic outcomes than when taken alone. 

Although MDMA and LSD have both been known for some time now for their therapeutic potential- with MDMA, in particular, receiving attention from ongoing trials of the drug and psychotherapy, there is currently very little research showing how the drugs may work in tandem. 

While LSD is known to induce feelings of ego dissolution that can result in introversion and anxiety, MDMA is known to enhance feelings of comfort and wellbeing. As such, the researchers suspect that MDMA may be able to 'take the edge' off of LSD. 

"The potential of MDMA-LSD is to create a psychological state that may have the benefits of both substances and have longer-lasting effects than standalone psilocybin or LSD," says Dr. Matthias Liechti, a professor at the University of Basel and lead researcher of the study.

"Inducing an overall primarily positive acute response during psychedelic-assisted therapy is critical because several studies showed that a more positive acute experience is linked to a greater therapeutic long-term effect in patients."

 

Sources: VicePR Newswire

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
AUG 22, 2020
Drug Discovery & Development
Could a Drug for Bipolar Disorder Treat COVID-19?
AUG 22, 2020
Could a Drug for Bipolar Disorder Treat COVID-19?
Researchers have found that a drug currently used to treat bipolar disorder and hearing loss may also treat COVID-19 tha ...
AUG 24, 2020
Cell & Molecular Biology
A Shield Surrounds the Flexible SARS-CoV-2 Spike Protein
AUG 24, 2020
A Shield Surrounds the Flexible SARS-CoV-2 Spike Protein
Researchers know that the viruses including SARS-CoV-2 have a Spike protein that allows them to bind to receptors on hos ...
SEP 10, 2020
Drug Discovery & Development
Common Painkiller Increases Risk-Taking Behavior
SEP 10, 2020
Common Painkiller Increases Risk-Taking Behavior
Researchers from Ohio State University have found that the common painkiller, paracetamol ( also known as Tylenol and Pa ...
SEP 13, 2020
Drug Discovery & Development
Scientists Find Way to Reduce Inflammation from Vaccines
SEP 13, 2020
Scientists Find Way to Reduce Inflammation from Vaccines
Researchers from the University of Chicago have found a new way to reduce vaccine-related inflammation from adjuvants, a ...
SEP 03, 2020
Drug Discovery & Development
Combination of Cholesterol Lowering Drugs Effective in Reducing Heart Disease
SEP 03, 2020
Combination of Cholesterol Lowering Drugs Effective in Reducing Heart Disease
A recent European study found that individuals taking a combination of lipid-lowering therapeutics may reduce the risk o ...
OCT 18, 2020
Drug Discovery & Development
Virus-Mimicking Drug
OCT 18, 2020
Virus-Mimicking Drug
Scientists have found drug that a drug activates the body’s immune system by behaving like a virus and may make ce ...
Loading Comments...